Literature DB >> 17503985

Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia.

Xiang Yang Zhang1, Yun Long Tan, Dong Feng Zhou, Lian Yuan Cao, Gui Ying Wu, Colin N Haile, Therese A Kosten, Thomas R Kosten.   

Abstract

BACKGROUND: Free radical-mediated pathology has been implicated in the development of tardive dyskinesia (TD). Antioxidant defense system alterations and increased lipid peroxidation have been postulated as a possible mechanism for neuronal damage associated with TD. However, the relationship between antioxidant enzymes, lipid peroxidation products, and the severity of TD symptoms has not been determined within a single patient group.
METHOD: Plasma levels of malondialdehyde (MDA), a marker of lipid peroxidation, superoxide dismutase, glutathione peroxidase, and catalase were examined in 80 patients with schizophrenia (DSM-IV criteria) and TD (Schooler-Kane criteria) and 45 schizophrenia patients without TD. Results were compared to those of 50 age-, sex-, and smoking status-matched controls. Tardive dyskinesia severity was assessed using the Abnormal Involuntary Movement Scale, and patient psychopathology was assessed using the Positive and Negative Syndrome Scale.
RESULTS: Patients with TD had lower plasma superoxide dismutase, glutathione peroxidase, and catalase levels but higher MDA levels than those without TD. In the patients with TD, MDA levels were positively correlated with Abnormal Involuntary Movement Scale total score and with Positive and Negative Syndrome Scale negative subscore. Superoxide dismutase and catalase activities were inversely correlated with MDA levels.
CONCLUSIONS: Our data support the hypothesis that oxidative stress is involved in the patho-physiology of TD. These data also suggest a relationship between oxidative stress and the severity of dyskinesia in TD patients. Increased lipid peroxidation may likely be a result of decreased endogenous antioxidant enzyme activities in TD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503985     DOI: 10.4088/jcp.v68n0513

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  18 in total

Review 1.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

Review 2.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

3.  N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice.

Authors:  David-Marian Otte; Britta Sommersberg; Alexei Kudin; Catalina Guerrero; Onder Albayram; Michaela D Filiou; Pamela Frisch; Oznur Yilmaz; Eva Drews; Christoph W Turck; Andras Bilkei-Gorzó; Wolfram S Kunz; Heinz Beck; Andreas Zimmer
Journal:  Neuropsychopharmacology       Date:  2011-06-29       Impact factor: 7.853

4.  Association of SOD2, GPX1, CAT, and TNF genetic polymorphisms with oxidative stress, neurochemistry, psychopathology, and extrapyramidal symptoms in schizophrenia.

Authors:  Marija Bošković; Tomaž Vovk; Marko Saje; Katja Goričar; Vita Dolžan; Blanka Kores Plesničar; Iztok Grabnar
Journal:  Neurochem Res       Date:  2012-12-02       Impact factor: 3.996

5.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

6.  Methionine sulfoxide reductase: a novel schizophrenia candidate gene.

Authors:  Consuelo Walss-Bass; Maria Clara Soto-Bernardini; Teresa Johnson-Pais; Robin J Leach; Alfonso Ontiveros; Humberto Nicolini; Ricardo Mendoza; Alvaro Jerez; Albana Dassori; Ivan Chavarria-Siles; Michael A Escamilla; Henriette Raventos
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-03-05       Impact factor: 3.568

Review 7.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

8.  Identification of the mitochondrial MSRB2 as a binding partner of LG72.

Authors:  David-Marian Otte; Tamás Raskó; Mengzhe Wang; Michael Dreiseidler; Eva Drews; Hanna Schrage; Alexandra Wojtalla; Jörg Höhfeld; Erich Wanker; Andreas Zimmer
Journal:  Cell Mol Neurobiol       Date:  2014-07-31       Impact factor: 5.046

9.  An integrated machine learning framework for a discriminative analysis of schizophrenia using multi-biological data.

Authors:  Peng-Fei Ke; Dong-Sheng Xiong; Jia-Hui Li; Zhi-Lin Pan; Jing Zhou; Shi-Jia Li; Jie Song; Xiao-Yi Chen; Gui-Xiang Li; Jun Chen; Xiao-Bo Li; Yu-Ping Ning; Feng-Chun Wu; Kai Wu
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

10.  Glutathione Deficiency during Early Postnatal Development Causes Schizophrenia-Like Symptoms and a Reduction in BDNF Levels in the Cortex and Hippocampus of Adult Sprague-Dawley Rats.

Authors:  Marta Anna Lech; Monika Leśkiewicz; Kinga Kamińska; Zofia Rogóż; Elżbieta Lorenc-Koci
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.